Pfizer Inc. (PFE)
Activist Starboard Value Takes $1 Billion Stake in Pfizer
The drugmaker's shares have slumped as demand for Covid-19 vaccines and treatments has slowed.
Pfizer: Patent Fears Priced In
Pfizer's stock has delivered a 5% total return since early July, outperforming the broader U.S. market, reinforcing my bullish stance. The latest quarterly earnings showed YoY revenue growth, marking the first growth since FQ4 2022. My dividend discount model suggests that Pfizer's stock is extremely undervalued.
Is Pfizer a Buy Right Now or a Value Trap?
Pfizer has prepared for today's challenges
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Pfizer (PFE) stood at $28.61, denoting a -0.21% change from the preceding trading day.
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
A 5.8% forward-dividend yield is just one reason the hedge fund manager likes this stock.
Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here's why it matters
Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care cybersecurity following major attacks.
Lock In A Phenomenal Yield With Pfizer
Pfizer's stock has declined by 50% over several years, yet it maintains a nearly 6% dividend yield, making it a valuable long-term investment. The company's quarterly performance includes $13.3 billion in revenue, $2.7 billion in R&D expenditures, and a $0.6 adjusted EPS, with respectable growth. Pfizer's oncology investments, including the $40 billion Seagen acquisition, show substantial YoY revenue growth and a robust pipeline of new drugs.
3 Consistent Dividend Stocks for Passive Income: KO, PFE, MO
Everybody loves dividends, essentially investors' form of payday. And these companies have been paying shareholders consistently for years.
Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon
Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.
Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Pfizer's acquisition of Seagen for $43 billion enhances its ADC technology, potentially expanding its oncology franchise and driving future growth. PFE's development of the oral GLP-1 receptor agonist, Danuglipron, aims to capture the growing obesity and diabetes treatment market by 2028. The Company anticipates 11.4% revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization, despite challenges from declining COVID-related revenue.
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon , a bookrunner said on Monday.
PFE vs. NVO: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?
